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Background: Iliac vein compression syndrome (IVCS) results from compression of the left iliac vein by the overlying right
iliac artery against the pelvic brim. In many cases, patients are symptomatic. In symptomatic cases, management consists
of angioplasty and stenting. Although therapy is often initially successful, factors associated with long-term outcome have
been poorly defined. The purpose of this study was to identify factors associated with stent patency.
Methods: The medical records of all patients who underwent iliac vein percutaneous transluminal angioplasty and stenting
from January 1996 to December 2006 for symptomatic IVCS were reviewed retrospectively. There were 50 women and
8 men, with a mean age of 42 years (median, 39 years; range, 17-71 years). Primary, assisted primary, and secondary
patency rates were determined. Patient characteristics and clinical variables were evaluated by univariate and multivariate
analysis to determine association with vein patency.
Results: Symptoms consisted of lower extremity swelling (81%) and lower extremity pain (67%). Iliac vein obstruction was
treated with pharmacologic thrombolysis (31% of patients) and mechanical thrombus fragmentation (17% of patients).
The primary, assisted primary, and secondary patency rates of angioplasty/stenting were 74.1%, 79.7%, and 85.8% at
1 year and 38.1%, 62.8%, and 73.8% at 5 years, respectively. Using a Cox proportional risk model, male sex (hazard ratio,
6.5; P  .001), recent trauma (hazard ratio, 5.3; P  .001), and age younger than 40 years (hazard ratio, 3.8; P  .015)
were associated with decreased primary patency. In the absence of any risk factors, primary patency was 94.4% at 1 year
and 63.0% at 5 years, decreasing to 28.6% and 0% for two or more risk factors.
Conclusions: Patency rates for iliac vein percutaneous transluminal angioplasty and stenting in patients with IVCS can
potentially be predicted on the basis of a multivariate model. Assessing risk factors allows for patient stratification and
appropriate clinical decision making. Prospective validation of these variables is necessary. ( J Vasc Surg 2007;46:743-9.)Symptomatic iliac vein compression syndrome (IVCS),
known also as May-Thurner syndrome, is uncommon. Al-
though the prevalence of this anatomic abnormality in the
population has been documented as 22% to 33% in autopsy
series,1-3 it is often asymptomatic and can therefore be
easily overlooked in the workup of acute iliofemoral deep
venous thrombosis, especially in patients who do not fit the
classic picture. IVCS is a condition of venous compression
by the overlying iliac artery, usually the left common iliac
vein by the right iliac artery. Strictures in the common iliac
vein were first described by McMurrich2 in 1908. How-
ever, it was not until 1957 that May and Thurner3 pro-
posed that the pulsatile right iliac artery may be the cause of
chronic left iliac vein changes. The clinical features of this
syndrome were described by Cockett and Thomas4 in
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doi:10.1016/j.jvs.2007.05.0481965. Patients often present with left leg swelling and pain
secondary to acute thrombosis, generally involving the
entire leg (including the thigh). The syndrome is particu-
larly evident in young to middle-aged women, especially
after multiple pregnancies. Alternatively, patients may
present chronically with symptoms of venous insufficiency
inadequately treated by compression stockings, intermit-
tent leg elevation, and good exercise for the calf muscle
pump. If symptoms do not respond to such a program or
actually worsen with this program, this syndrome must be
suspected, especially if it involves the left leg. Men also can
present with this syndrome, and although leg swelling is
most common in men, an ipsilateral varicocele has been
reported in a male patient with iliac vein compression.5
In a previous report from our institution, we described
our experience with and approach to the management of
IVCS.6 Over the past decade, we have noted that stent
patency rates are variable. We therefore sought to identify
factors that influenced patency rates, to adapt treatment
approaches appropriately. This study presents a retrospec-
tive review of our 10-year experience with endovascular
treatment of IVCS, specifically addressing risk factors for
decreased stent patency.
METHODS
Data source. Themedical records of 145 patients who
underwent venous interventions from January 1996 to
December 2006 were reviewed. These patients are part of a
743
JOURNAL OF VASCULAR SURGERY
October 2007744 Knipp et alclinical practice in which patients are followed up closely
with duplex imaging after their interventions; flow is as-
sessed at regular intervals. Patients with IVCS diagnosed by
magnetic resonance venography, contrast phlebography, or
intravascular ultrasonography (IVUS) and who underwent
iliac vein angioplasty with stenting were then identified for
retrospective analysis. The IVUS criterion for IVCS is an
absence of a visible venous lumen surrounding the IVUS
catheter, generally at the level of the right common iliac
artery. Exclusion criteria included an index procedure per-
formed at an outside hospital, angioplasty without stent
placement, and no intervention.
Demographic and clinical information. Each chart
was reviewed for sex, age at the onset of symptoms, severity
of the symptoms, a family history of hypercoagulable dis-
orders, recent airline travel or other causes of immobility,
recent trauma, recent surgical procedure, recent pregnancy,
a history of malignancy, medications (including hormonal
contraception or hormone-replacement therapy), obesity
(defined as BMI 30.0 kg/m2 or documentation of a
diagnosis of obesity), and medical conditions including
lower extremity deep venous thrombosis, pulmonary em-
bolism, or hypercoagulable disorder. Basic CEAP scores
were determined from clinical notes and from documented
reflux studies before stenting, when available.7
Hypercoagulable disorders. Patients were classified
as having a hypercoagulable disorder if they had one of
the following: factor V Leiden mutation heterozygosity or
homozygosity, protein C or S deficiency, antithrombin
deficiency, increased factor VIII level, prothrombin
20210A mutation, or methyltetrahydrofolate reductase
mutation heterozygosity or homozygosity with concomi-
tant hyperhomocysteinemia. In cases in which the hyper-
coagulable workup was either incomplete or missing, a
clinical assessment was made. Evidence of hypercoagulable
disorder—such as a personal or family history of recurrent
deep venous thrombosis or pulmonary embolism, espe-
cially in the absence of explanatory factors, or multiple
miscarriages—led to a presumptive diagnosis of hyperco-
agulability.
Procedural data. Each case was reviewed for the im-
aging modalities used (duplex ultrasonography, computed
tomography, magnetic resonance venography, contrast
phlebography, or IVUS), location of the thrombus (ilioca-
val, iliac, iliofemoropopliteal, and so on), interventions
used (chemical thrombolysis, mechanical thrombus frag-
mentation, venoplasty, stent placement, arteriovenous fis-
tula creation, or inferior vena cava filter placement), the
lytic agent used (if any), duration of thrombolysis, vessels
lysed, vessels stented, number and size of stents, and total
stent length.
Outcome variables. The primary outcome variable
was primary stent patency. Additional outcome variables
were assisted primary patency, secondary stent patency, and
subjective symptom improvement. Assisted primary pa-
tency was defined as uninterrupted stent patency after any
additional rescue procedure (eg, venoplasty of in-stent
restenosis). Secondary patency was defined as restoration ofpatency after a procedure (eg, lysis of an occluded stent
with restoration of patency). Duration of follow-up was
defined as the time from the initial intervention until the
most recent clinical encounter. An event was defined as a
loss of primary patency (eg, an assist procedure was re-
quired), loss of assisted primary patency (eg, a lysis proce-
dure was required), or loss of secondary patency (eg, the
stent became permanently occluded or an alternate bypass
procedure was performed).8 If no event occurred, the
duration was censored for statistical purposes at the most
recent objective duplex ultrasound scan or phlebogram
demonstrating stent patency.
Statistical analysis. Patient characteristics and clinical
variables were evaluated to determine association with stent
patency. Univariate analysis of patient characteristics or
technical variables was performed via Kaplan-Meier analysis
with log-rank comparison. Any variables found to be sig-
nificant in univariate analysis with P  .10 were entered
into a Cox proportional hazards model. P  .05 was
considered significant in the final analysis. Variables are
presented as mean  SD or SE as noted. All statistical
calculations were performed with the SPSS software pack-
age, version 11.0.1 (SPSS Software Inc, Chicago, Ill).
RESULTS
Demographic information. From a 10-year period
(1996-2006) of our venous reconstruction database, pa-
tients treated with endovascular therapy for IVCS were
identified. Fifty-eight patients were treated, which included
50 women and 8 men. The mean age at presentation was
41.6  13.2 years (median, 39 years; range, 17-71 years;
Table I).
Clinical presentation and follow-up. All patients
presented with left-sided symptoms; in 7 patients, the
symptoms were bilateral. The time between the initial onset
Table I. Patient demographics
Variable Data
Total No. patients 58
Female 50 (86%)
Age (y) 41.6  13.2
Average follow-up (mo) 29.7  30.3
Unilateral symptoms 51 (88%)
Lower extremity swelling 47 (81%)
Venous claudication or groin pain 39 (67%)
Phlebitis 6 (10%)
Phlegmasia alba dolens 2 (3%)
Phlegmasia cerulean dolens 9 (16%)
Hypercoagulable disorder 19 (33%)
Obesity 21 (36%)
Family history of clotting disorders 14 (24%)
Lower extremity deep venous thrombosis 52 (90%)
Pulmonary embolism 11 (19%)
Postsurgical 11 (19%)
Estrogen-based contraception 15 (26%)
Hormone-replacement therapy 7 (12%)
Recent trauma 8 (14%)of symptoms and presentation ranged from less than 1 day
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of patients with thrombotic disease, the time from the onset
of clinical symptoms to initial intervention was 59 months
(SE, 15 months; range, 0-376 months). This time repre-
sented the interval between presentation to a physician and
the time until referral to our institution. Clinical presenta-
tions included lower extremity swelling (n  47), lower
extremity pain (n 39), phlebitis (n 6), phlegmasia alba
dolens (n  2), and phlegmasia cerulea dolens (n  9). By
CEAP classification, 47 (81%) were class C3 (edema), 12
(21%) were class C4a or C4b (skin changes including
pigmentation, lipodermatosclerosis, or atrophie blanche),
and 4 (7%) were classes C5 or C6 (healed or active ulcers).
Eighteen patients (31%) underwent reflux studies: photo-
plethysmography, air plethysmography, or venous ultra-
sonography. Symptoms were from a postthrombotic etiol-
ogy in 52 patients (90%) and from a primary obstructive
etiology in 6 patients (10%). Venous reflux was noted in 12
(21%) patients: in 9 patients, reflux was limited to the deep
system only, and in 3 patients there was reflux in the deep
and superficial systems. Reflux was documented in the great
saphenous vein in two patients, the external iliac vein in two
patients, the common femoral vein in four patients, and the
popliteal vein in three patients. CEAP scores are tabulated
in Appendix I (online only). The average follow-up was
29.7  30.3 months (median, 20 months; range, 0-124
months). Of the entire treated group (n 58), 35 patients
(60%) underwent formal hypercoagulability testing, of
which 16 tests results were positive; the remaining 23
patients (40%) were assessed by subjective analysis, and 3
were classified as positive (Table II). A total of 52 patients
(90%) had a current or prior deep venous thrombosis. A
total of 21 patients (36%) were obese, 15 patients (26%)
Table II. Hypercoagulable disorders
Patient
No. Hypercoagulable disorder
1 Factor V Leiden homozygote
2 Factor V Leiden homozygote
3 Factor V Leiden homozygote
4 Factor V Leiden heterozygote
5 Factor V Leiden heterozygote
6 Factor V Leiden heterozygote
7 Factor V Leiden heterozygote
8 Factor V Leiden heterozygote
9 Factor V Leiden heterozygote, prothrombin
20210A mutation, protein C deficiency
10 Protein S deficiency, prothrombin 20210A mutation
11 Protein C and S deficiency
12 Protein S deficiency
13 Antithrombin deficiency
14 Methyltetrahydrofolate reductase mutation with
hyperhomocysteinemia
15 Increased factor VIII
16 Clinical assessment
17 Clinical assessment
18 Clinical assessment
19 Unspecified hypercoagulable disorderwere taking oral contraceptive pills, 14 patients (24%) had afamily history of clotting disorders, 11 patients (19%) had a
history of pulmonary embolism, 11 patients (19%) had
undergone recent surgery, 8 patients (14%) were victims of
recent generalized blunt trauma, 7 patients (12%) were
taking hormonal replacement medications, and 7 patients
(12%) had been recently pregnant.
Diagnostic testing. Evaluation in all patients con-
sisted of a complete history and physical examination.
Documentation of iliac vein compression by radiographic
evidence was present in all cases. Subsequent evaluation
included phlebography in all patients. The diagnosis was
made by IVUS in 36 (62.1%) cases, by magnetic resonance
venography in 9 (15.5%) cases, and by phlebography only
in the remaining 13 (22.4%) cases. Duplex ultrasound imag-
ing was performed in 57 (98.1%) cases. In 52 (90%) patients,
deep venous thrombosis (current or byhistory)was present; in
2 cases, the thrombus was bilateral, but in both cases the
contralateral thrombus was not in the iliac vein.
Treatment and results. All treated patients under-
went successful recanalization. Subjectively, of the 56 pa-
tients with follow-up data available, improvement was
noted in 45 (80%), and no change was noted in 19 (20%);
no patient described worsening of symptoms. Adjunctive
treatments included pharmacologic thrombolysis, with a
mean duration of 2.2 1.2 days (n 18), and mechanical
thrombus fragmentation (n 10). All patients were treated
with angioplasty and stents. The mean number of stents
was 2.7  1.4 (median, 3; range, 1-7). The mean stent
length was 137 73mm. Stents used in the study are listed
in Appendix II (online only) and ranged in diameter from 8
to 16 mm, with 41% being 16 mm. This is consistent with
our earlier practice.6 All stents were placed in the left iliac
vein and extended into the inferior vena cava. One patient
had stents placed concomitantly in the right iliac vein and
the brachiocephalic vein. Inferior vena caval filters were
placed in 18 patients. Six patients underwent subsequent
formation of an arteriovenous fistula, typically consisting of
an anastomosis between a branch of the great saphenous
vein and the superficial femoral artery. Arteriovenous fistu-
las were constructed because of concern of poor inflow into
the stented area. Of the six patients who had arteriovenous
fistulas, no fistula currently remains patent. Four were taken
down by angioembolization, and two spontaneously
closed. Of the patients who underwent arteriovenous fis-
tula creation, one has an open stent without further inter-
ventions, one has an open stent with a rescue procedure for
stenosis, two have open stents after lytic therapy, and two
have occluded stents. Additional operations were per-
formed in six patients near the time of the initial stent
placement, exclusive of cutdowns for percutaneous vascular
access. In one patient, a left saphenopopliteal vein anasto-
mosis and bypass was performed along with a left axillary
vein transplantation to the left saphenous vein and a left
saphenous external valvuloplasty. A second patient under-
went cutdown for venous thrombectomy of the femoral
vein. A third patient underwent creation of an arterio-
venous fistula, common femoral vein venoplasty for web
removal, and patch venoplasty, and a fourth patient under-
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tional patients underwent venoplasty for web removal only.
Complications. In one case the most caudal Wallstent
(Schneider, Minneapolis, Minn) in the left femoral vein was
removed as a result of thrombosis, and in a second case a
groin cutdown was performed for a retained balloon. In
one patient, a 4-cm Wallstent placed in the left common
iliac vein migrated into the inferior vena cava despite place-
ment at the crossing of the right common iliac artery and
had to be removed percutaneously. After this, a minimum
of 6-cm-longWallstents were used to ensure docking of the
stent in the distal postthrombotic intima. Two patients had
groin hematomas, one of which was associated with a
retroperitoneal hematoma.
Patency and follow-up. Duplex ultrasonography,
phlebography, or both were performed in 54 patients
(93.1%) after their initial stent procedure. One patient was
lost to follow-up after discharge from the hospital. Life-
table analysis of primary, primary assisted, and secondary
stent patency is shown in Fig 1. Primary patency was 74.1%
at 12 months (SE, 6.3%; n  29) and 38.1% at 60 months
(SE, 12.4%; n  4). Assisted primary patency was 79.7% at
12 months (SE, 5.8%; n  31) and 62.8% at 60 months
(SE, 10.5%; n  7). Secondary patency was 85.8% at 12
months (SE, 5.0%; n  35) and 73.8% at 60 months (SE,
9.7%; n  7). One death unrelated to treatment occurred
3.5 years after successful intervention.
After stent placement, 42 patients (72%) received war-
farin for a variable length of time based on their underlying
thrombotic risk potential. An additional 11 patients (19%)
received antiplatelet therapy with clopidogrel, aspirin, or
both for a minimum of 6 weeks. For five patients, data were
not available regarding anticoagulation.
Univariate analysis. We sought to determine whether
stent patency was affected by patient or thrombus charac-
teristics or treatment variables. Kaplan-Meier univariate
Fig 1. Life-table analysis of primary, primary assisted, and
secondary patency.analysis was performed for each variable vs primary patency.Log-rank comparisons were performed. Variables with P .1
were entered into a Cox proportional hazards model for
multivariate analysis. Variables found significant in univar-
iate analysis at P .10 were trauma, male sex, placement of
an inferior vena cava filter, mechanical thrombus fragmen-
tation, creation of an arteriovenous fistula (as part of the
index procedure), obesity, stent longer than 180 mm,
hypercoagulable state, age younger than 40 years, and
more than three stents (Table III).
Multivariate analysis. Factors associated with de-
creased primary patency were male sex (hazard ratio, 6.5; P
 .001), recent trauma (hazard ratio, 5.3; P  .001), and
age younger than 40 years (hazard ratio, 3.8; P  .015; Table
IV). Figures 2 to 4 demonstrate the variation in primary,
assisted primary, and secondary patency relative to the
number of risk factors identified by multivariate analysis. In
patients with no risk factors, primary patency rates were
94.4% at 1 year and 63.0% at 5 years. These rates decreased
to 74.6% at 1 year and 37.3% at 5 years for one risk factor
and 28.6% at 1 year and 14.3% at 2 years for two risk factors.
Similarly, assisted primary patency rates for patients with no
risk factors were 94.4% at 1 and 5 years, decreasing to 86.3%
at 1 year and 61.3% at 5 years for patients with one risk
factor and 28.6% at 1 year and 14.3% at 2 years for two risk
factors. Secondary patency rates were 94.4% at 1 and 5 years
for no risk factors, 92.2% at 1 year and 73.7% at 5 years for
one risk factor, and 42.9% at 1 year and 28.6% at 4 years for
patients with two risk factors.
DISCUSSION
Factors associated with decreased primary patency were
male sex, recent trauma, and age younger than 40 years. It
is important to note that with none of these three factors
Table III. Univariate analysis for primary patency
Variable P value
History of trauma .0001
Male sex .0002
IVC filter .0009
Mechanical thrombus fragmentation .0064
Arteriovenous fistula .0117
Obesity .0132
Stent length 180 mm .0379
Hypercoagulable state .0680
Age 40 y .0846
More than 3 stents .0919
IVC, Inferior vena cava.
Table IV. Multivariate model of primary patency
Covariate P value Hazard ratio 95% CI
Male sex .001 6.5 2.1-20.1
Recent trauma .001 5.3 1.9-14.6
Age 40 y .015 3.8 1.3-11.0
CI, Confidence interval.present, the primary patency at 1 year in our study was
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factors, patency decreased to 28.6% and 14.3% at 1 and 2
years, respectively.
The right iliac artery most commonly crosses the left
common iliac vein just distal to the iliac bifurcation, as was
the case for all patients in this study, although variations of
this anatomy have been described.9 Compression of the
vein by the overlying artery is quite common and generally
painless. In one study of 50 consecutive asymptomatic
patients, 24% demonstrated more than 50% compression
Fig 2. Kaplan-Meier analysis of primary stent patency by number
of risk factors. In the one case of a patient with all three risk factors,
the stents occluded within 24 hours and required immediate
reintervention; secondary patency remained durable beyond 2
years. Comparisons were made by using the log-rank statistic.
Fig 3. Kaplan-Meier analysis of primary assisted stent patency by
number of risk factors. Comparisons were made by using the
log-rank statistic.and 66% showed more than 25% compression by usingcomputed tomography with intravenous contrast and axial
images with 2- to 5-mm slice width.10 However, in some
patients this compression leads to significant symptoms,
such as pain and swelling of the entire leg, deep venous
thrombosis, or phlegmasia cerulea dolens, necessitating
intervention. It is currently unclear why some patients
progress to symptomatic obstruction whereas others have
no sequelae in this apparently common anatomic scenario.
Raju and Neglen9 proposed that iliac vein compression
serves as a permissive lesion, similar to esophageal reflux in
the etiology of esophageal cancer, and that patients with
asymptomatic lesions should be educated and followed up
closely for the early identification of acute occlusion.
Several methods are available to help to make this
diagnosis, including air plethysmography, venous duplex
ultrasound imaging, magnetic resonance imaging (mag-
netic resonance imaging/magnetic resonance venogra-
phy), phlebography, computed tomographic imaging, and
IVUS.6,9,11-14 IVUS led to diagnosis in many of the patients
in this study, followed by magnetic resonance imaging/
magnetic resonance venography and phlebography.
Treatment involves both open surgical and endovascu-
lar interventions. Open procedures include venous patch
angioplasty, division and relocation of the right common
iliac artery, and placement of a silicon elastic bridge over the
iliac vein.1 A venous bypass (the Palma procedure) is also
possible if the iliac vein is too severely damaged to be
repaired. Endovenous techniques have the obvious advan-
tage of not necessitating a major abdominal dissection. In a
large group of 447 limbs with chronic nonmalignant ob-
struction with greater than 50% stenosis, after venoplasty
and stenting, approximately 50% of patients were com-
pletely relieved of pain, and approximately one third were
Fig 4. Kaplan-Meier analysis of secondary stent patency by num-
ber of risk factors. Comparisons were made by using the log-rank
statistic.relieved of swelling.15 Additionally, more than half of open
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rected in this study.
Although technical success for endovenous angioplasty
and stenting has generally exceeded 87% to 95% and pri-
mary patency has ranged from 79% to 95% (1 year) to 73%
(3 years),16-23 very few data exist on factors that relate to
long-term success. The most information to date comes
from Neglen and Raju.24 Over a 42-month follow-up, only
23% of patients showed no in-stent restenosis, 61% of
patients had greater than 20% in-stent restenosis, and 15%
of patients demonstrated greater than 50% in-stent reste-
nosis. More limbs with thrombotic disease vs nonthrom-
botic disease showed in-stent restenosis: 20% narrowing
was documented in 63% vs 41%, and 50% narrowing was
documented in 23% vs 4%, respectively. Factors associated
with in-stent restenosis were thrombotic disease, thrombo-
philia, and stenting below the inguinal ligament. In this
study, long stent length was significant in univariate analy-
sis, as was thrombophilia (P .10); in multivariate analysis,
however, neither was independently associated with stent
patency. It is possible that our study was underpowered to
detect thrombotic disease as a risk factor, because only 6 of
58 patients presented without current or past thrombosis.
In the current study, we found recent trauma (mostly
general blunt trauma, not isolated trauma to the iliac vein)
to be associated with decreased stent patency, although
recent surgery was not associated with worse outcomes.
This may be because many of the surgical patients under-
went orthopedic procedures and appropriate prophylaxis
was used, whereas in cases of blunt trauma, no prophylaxis
is available and is often contraindicated in the immediate
posttrauma setting. Therefore, if patients have a predispos-
ing lesion, this may result in an acute thrombotic occlusion.
Limitations of this study involve its retrospective na-
ture, the limited number of patients evaluated, and the fact
that not all patients evaluated underwent a full hypercoagu-
lability workup. In addition, no quality-of-life assessment
was made after intervention. Advantages include the facts
that all patients were managed by the same team, the
patients underwent close follow-up, and only symptomatic
patients with objectively diagnosed iliac vein compression
were treated.
In conclusion, in our experience, male sex, trauma, and
young age were associated with decreased stent patency.
These factors should be considered carefully when venous
angioplasty and stenting are planned for left iliofemoral
venous compression. We plan to evaluate this predictive
model in a future prospective clinical trial.
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C(3,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(0,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(3,4a,s)E(s)A(d)P(r,o) C(3,s)E(s)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(2,3,s)E(s)A(d)P(r,o) C(3,s)E(s)A(x)P(o)
C(0,s)E(s)A(x)P(o) C(2,3,s)E(s)A(x)P(o)
C(0,a)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(1,s)E(s)A(x)P(o) C(0,s)E(s)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(2,3,4a,s)E(s)A(x)P(o)
C(2,3,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(0,s)E(s)A(x)P(o) C(1,s)E(x)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(3,4a,s)E(s)A(x)P(o) C(0,s)E(s)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(4a,5,s)E(s)A(s,d)P(r,o)
C(3,4b,6,s)E(s)A(d)P(r,o) C(3,s)E(s)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(3,4a,6,s)E(s)A(s,d)P(r,o) C(3,a)E(s)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(2,3,4a,s)E(p)A(s,d)P(r,o)
C(3,s)E(s)A(x)P(o) C(3,s)E(s)A(x)P(o)
C(2,3,4a,s)E(p)A(d)P(r,o) C(0,s)E(p)A(d)P(r,o)
C(2,3,s)E(p)A(d)P(r,o) C(3,4a,6,s)E(s)A(x)P(o)
C(0,s)E(s)A(x)P(o) C(3,4a,s)E(s)A(x)P(o)
C(3,4a,s)E(s)A(d)P(r,o) C(3,s)E(s)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(2,3,s)E(x)A(x)P(o)
C(3,s)E(s)A(x)P(o) C(2,3,s)E(s)A(x)P(o)
C(2,3,s)E(s)A(d)P(r,o) C(2,3,4a,s)E(s)A(d)P(r,o)
Where an x is indicated, there were insufficient data to provide an
assessment.Appendix II (online only). List of stents used in
endovascular treatment
Schneider Wallstent (14  40, 14  40, 12  60, 10  68)
SchneiderWallstent (16 40, 14 40, 12 40, 12 40, 12 40)
Schneider Wallstent (12  60, 12  60, 12  40)
Schneider Wallstent (14  60, 12  60, 12  40)
Schneider Wallstent (14  40, 12  40)
Schneider Wallstent (14  60, 12  60, 12  60, 10  68)
Schneider Wallstent (16  40, 14  40, 14  40, 12  40)
Vivant Z stent (15  50)
Schneider Wallstent (12  60)
Schneider Wallstent (14  40, 12  60, 12  40, 10  68)
Schneider Wallstent (14  40, 12  60, 14  60)
Schneider Wallstent (16  60)
Schneider Wallstent (14  40, 12  45, 12  40, 10  96)
Cordis SMART Stent (14 40, 14 40, 12 40, 12 40, 8 60)
Schneider Wallstent (14  60, 14  40, 12  60, 12  40)
Schneider Wallstent (16  40, 16  40, 14  40, 14  40,
14  40, 14  40, 10  68)
Schneider Wallstent (16  60)
Schneider Wallstent (14  40, 14  40)
Cordis SMART Stent (12  40, 12  40)
Schneider Wallstent (16  60, 16  60, 12  90)
Schneider Wallstent (16  60, 12  60, 12  60)
Schneider Wallstent (16  60, 12  60, 12  60, 12  40)
Schneider Wallstent (16  60, 14  60, 12  60)
Schneider Wallstent (14  60, 12  40, 10  68)
Schneider Wallstent (16  60, 16  60)
Schneider Wallstent (14  40)
Schneider Wallstent (16  40, 14  60, 14  40, 12  60, 12  60, 10
 68)
Schneider Wallstent (16  60, 14  60, 12  90)
Schneider Wallstent (12  60, 12  40)
Schneider Wallstent (16  60, 14  60, 14  60)
Schneider Wallstent (10  40, 10  60, 10  94)
Schneider Wallstent (16  60, 14  40, 12  40, 12  40, 12  40)
Schneider Wallstent (16  60)
Schneider Wallstent (14  60, 12  90)
Schneider Wallstent (16  60)
Schneider Wallstent (16  60, 12  60, 12  68)
Schneider Wallstent (14  60)
Palmaz 308 stent, Palmaz 308 stent, Schneider Wallstent (12  60, 10 
42, 10  42)
Schneider Wallstent (16  60, 16  40, 16  40, 16  40)
Schneider Wallstent (10  68, 10  38, 14  40)
Schneider Wallstent (12  40)
Schneider Wallstent (16  60)
Schneider Wallstent (14  60, 12  60)
Cordis SMART Stent (14 60, 14 60, 14 40, 14 40, 12 40)
Schneider Wallstent (14  40, 12  90, 10  60)
Schneider Wallstent (16  60, 14  40, 12  60)
Schneider Wallstent (12  40, 12  40)
Schneider Wallstent (16  60, 14  40)
Schneider Wallstent (14  60)
Cordis SMART Stent (14  60, 14  40)
Schneider Wallstent (16  60)
Schneider Wallstent (14  40, 14  40, 12  40)
Schneider Wallstent (12  40, 10  68)
Schneider Wallstent (14  40)
Schneider Wallstent (16  60)
Schneider Wallstent (16  40)
SchneiderWallstent (14 60) left, SchneiderWallstent (14 60) right
Schneider Wallstent (16  40)
The numbers for each stent represent the size of the stent in millimeters
(diameter  length).
Wallstent (Schneider, Minneapolis, Minn) Palmaz 308 (Johnson & John-
son, Warren, NJ), Cordis SMART stent (Johnson & Johnson, Warren, NJ),
Vivant Z stent (PFM AG, Cologne, Germany).
